Drug Industry Invests $1 Billion For Antibiotic Development

Before the discovery of antibiotics, tuberculosis was the second most common cause of death in the US. Today, thanks to antibiotics, the few who contract the disease rarely die.

But as TB and other once-easily cured diseases grow increasingly antibiotic resistant, the very real fear is that medicine may run out of treatment options, leading to epidemics dwarfing COVID-19.

To head-off that kind of future, two dozen pharmaceutical firms have invested nearly $1 billion creating the AMR Action Fund with the goal of developing 2-4 new antibiotics by 2030.

AMR – antimicrobial resistance – arises when infectious disease pathogens become resistant to existing medicines. Tuberculosis is one of them, as are several others including the much publicized MRSA.

“AMR has the potential to render diseases that are relatively easy to treat today virtually incurable,” said Dr. Paul Stoffels, vice chairman of the executive committee and chief scientific officer, Johnson & Johnson.

“Left unchecked, AMR could significantly eclipse the global health challenge that the world is facing currently with COVID-19,” he said in a statement announcing the launch of the AMR Action Fund.

The initial funding pledges from the bioscience and drug firms – including $100 million pledged each by Johnson & Johnson and Pfizer – will be supplemented by non-industry partners, the Fund says on its website.

Explaining that “drug resistant bacteria are developing faster than new antibiotics can reach the market,” the Fund says there are few antibiotics in clinical development to meet current and anticipated needs. The reason is that the market for antibiotics “doesn’t support the level of investment needed to maintain a robust antibiotic pipeline.”

The website goes on to explain that smaller biotech firms have trouble financing trials of the antibiotics they do develop. Some that have developed new antibiotics “have declared bankruptcy or exited this space,” cautions the Fund, “Due to the lack of commercial sustainability, resulting in the loss of valuable expertise and resources.”

To achieve its goal of bringing to market the new antibiotics in a decade, the Fund said it “will invest in smaller biotech companies focused on developing new antibiotics that address the highest priority public health needs.”

Specifically, the AMR Action Fund will:

  1. “Invest based on the WHO/CDC priority lists of pathogens, with the goal to address major unmet needs and maximize public health impact.
  2. “Prioritize novel antibacterial treatments, as recognized by leading public health agencies, with significant and differentiated clinical utility and that reduces patient mortality.
  3. “Invest across all stages of clinical development.”
Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Essential Strategies for 2024: Remote Training
General Interest

Essential Strategies for 2024: Remote Training

Steps to Nurture a Multigenerational Workforce
General Interest

Steps to Nurture a Multigenerational Workforce

Tips to Cultivate a Compelling Employer Brand
General Interest

Tips to Cultivate a Compelling Employer Brand

Green Key Names 3 New Partners in 2024
General Interest

Green Key Names 3 New Partners in 2024

#WeAreGreenKey: Spotlight on Samantha Desena 
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Samantha Desena 

Why Companies are Already Recruiting Interns for 2025
General Interest

Why Companies are Already Recruiting Interns for 2025

Todd Gabianelli Selected as an Old Master at Purdue University 
Pharma

Todd Gabianelli Selected as an Old Master at Purdue University 

Navigating the Surge of Respiratory Illnesses Across the U.S.
General Interest

Navigating the Surge of Respiratory Illnesses Across the U.S.

Gen Z: Catalysts for Workplace Evolution in 2024
General Interest

Gen Z: Catalysts for Workplace Evolution in 2024

The Office Real Estate Dilemma
General Interest

The Office Real Estate Dilemma

#WeAreGreenKey: Spotlight on Rich Egloff
Architecture + Engineering Leadership + Management

#WeAreGreenKey: Spotlight on Rich Egloff

From the Big Quit to the Big Stay
General Interest

From the Big Quit to the Big Stay

Wrapped up: Green Key Unlocked 2023
Accounting + Finance Architecture + Engineering General Interest Healthcare Information Technology

Wrapped up: Green Key Unlocked 2023

Job Market Trends to Look For in 2024
General Interest

Job Market Trends to Look For in 2024

Wrapped Up: #WeAreGreenKey 2023
General Interest

Wrapped Up: #WeAreGreenKey 2023

Is Curiosity a Recruiter’s Superpower?
General Interest

Is Curiosity a Recruiter’s Superpower?

Best Practices for Performance Reviews
General Interest

Best Practices for Performance Reviews

Latest Blog Posts
View All Posts
Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Mary-Kate Bula, recruiter on Green Key’s Pharma team was recently selected as Assistant Coach of the USA Women’s Flag Football...
Read More
Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

In today’s dynamic business landscape, understanding market trends, customer preferences, and industry insights is essential for staying ahead of the...
Read More
#WeAreGreenKey: Spotlight on Kyle Gierke

#WeAreGreenKey: Spotlight on Kyle Gierke

We met up with Kyle Gierke, Staffing Manager on the Healthcare team at Green Key. Kyle started his journey at...
Read More